Rossari Biotech Ltd

- There is no mention of any planned new fundraising through debt or equity in the transcript. - The company plans to focus on reducing existing debt, targeting to become debt-free over the next 18 months. - Current long-term debt stands at around Rs. 200 crore, with additional short-term working capital borrowings. - Capital expenditure for FY27 is planned between Rs. 50 crore to Rs. 75 crore, which is a moderated spend compared to earlier plans. - The company is optimizing cash flows by shedding non-core assets and divesting certain consumer-focused businesses to improve liquidity and reduce debt. - No timelines or numbers have been provided for divestments, though they are expected to happen strategically over 1-2 years or more. - Promoters have denied rumors of selling stake or exiting the company.

- FY27 CAPEX plan is Rs. 50 crore to Rs. 75 crore, including: - New pharma facility expansion - Aroma chemical facility expansion - Earlier large CAPEX plans (Rs. 190 crore across multiple sites) have been rephased due to market conditions; some parts postponed to optimize cash flow and returns - New R&D facility set up in Navi Mumbai consolidating existing operations, supporting faster innovation and scale-up - Ethoxylation capacity expanded to 66,000 metric tons per annum at Dahej, improving supply reliability - Ongoing focus on capacity utilization and operational efficiencies to support growth - Some capital spending to continue on high-margin segments like pharma and aroma chemicals, with careful optimization to manage cash flows and improve ROCE - No specific timeline given for some smaller CAPEX and pilot projects; plans will be phased over FY27 and possibly FY28

- Targeting a minimum 15% growth in FY27 driven by expansions in agro, pharma, personal care, and textile exports (including markets like Bangladesh, Thailand, Turkey, and Brazil). - New premix facility in Animal Health Nutrition (AHN) expected to ramp up revenues starting FY27, supporting growth. - CAPEX of Rs. 50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments. - Growth expected over the next 2-3 years through new customer additions and expansion in high-margin segments such as pharma, oil and gas, aroma, personal care, food processing, and institutional chemicals. - Core B2B businesses to drive growth with latent growth in Agro, Textile, AHN, and Personal Care. - Export growth anticipated to outperform domestic textile growth, supported by product approvals and expanding global footprint. - Plans to divest non-core, lower-margin consumer businesses to improve focus and profitability in core segments.

- The company expects a minimum of 15% revenue growth in FY27 driven by expansion in personal care, agro, textile exports, and animal health and nutrition (AHN) segments. - Institutional business is projected to breakeven or achieve profitability by FY27, improving overall earnings. - Core B2B operations deliver around 14% EBITDA margin; efforts continue to improve margins via better product mix and cost control. - Growth drivers include ramp-up of capacities commissioned in FY26, new ethoxylation capacity, and new product segments like pharma, oil & gas. - EBITDA margins expected to be maintained at current levels (~12-13%) in FY27 with improvements from high-margin segments anticipated in the second half. - The company plans divestment of non-core/loss-making businesses to enhance profitability, though timelines may extend beyond FY27. - Operating leverage and efficiency improvements are expected to support margin expansion over the next 2-3 years.

The transcript on page 19 and surrounding pages does not explicitly mention specific details about the current or expected order book or pending orders in quantified terms. However, relevant points related to demand and order pipeline include: - Utilization levels for ethoxylation capacity are very high (90%-100%), running continuously, indicating strong order demand. - The company sees a good pipeline of projects across its sales and business development teams worked on in the last 12 months. - No demand-side challenges reported despite raw material price increases; orders remain robust. - Growth drivers include North America for personal care and agro businesses, ramping up exports in textiles through Bangladesh, Southeast Asia, Thailand, Turkey, and Brazil. - New premix facility at AHN starting revenues this quarter is expected to contribute significantly. - Institutional business expected to break even or become profitable by FY27 due to divestment of low-margin segments. Overall, the company signals confidence in a strong order pipeline and continued growth.